Side-by-side · Research reference

CortagenvsDermorphin

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED11/35 cited

BAnimal-StrongHUMAN-REVIEWED20/47 cited

Cortagen

Bioregulatory Tetrapeptide · Khavinson-School

TetrapeptideStructure

↓ LPO productsAntioxidant effectKozina 2007

AnimalEvidence level

Injectable · Animal models

Dermorphin

Opioid Peptide · μ-Receptor Agonist · Research Only

~30×Morphine potency

μ-selectiveReceptor typeNegri 1992

D-Ala²Unique featureAmiche 1998

Research only · ICV / SC (animal models)

01Mechanism of Action

Parameter

Cortagen

Dermorphin

Primary target

Cerebral cortex tissue — molecular targets under investigation

μ-opioid receptors (central and peripheral)Negri 1992 Steel 2014

Pathway

Antioxidant pathway modulation — suppression of LPO cascade, reduction of protein oxidative modificationKozina 2007

μ-receptor activation → G-protein coupling → adenylyl cyclase inhibition → neuronal hyperpolarization

Downstream effect

Decreased lipid peroxidation products, reduced oxidative protein damage, altered gene expression in cardiac tissueKozina 2007 Anisimov 2004

Potent analgesia, reduced nociceptive signaling, opioid-mediated CNS and peripheral effects

Feedback intact?

—

N/A — exogenous opioid agonist

Origin

Synthetic tetrapeptide derived from amino acid analysis of natural brain cortex peptide preparation CortexinAnisimov 2004

Phyllomedusa sauvagei and P. bicolor frog skin — gene-encoded with natural D-amino acid incorporationAmiche 1998 Mignogna 1992

Antibody development

—

Site-directed antibodies produced for detection and purificationCucumel 1996

02Dosage Protocols

Parameter

Cortagen

Dermorphin

Animal model dose (rat)

Injection protocol (dose not specified in abstracts)

Multiple injections over study period.

—

Avian model dose (chicken)

40-day injection courseKuznik 2008

Compared to epithalon in hypophysectomized and aged birds.

—

Human peripheral nerve study

Therapeutic course (protocol details not provided)

Posttraumatic recovery context — reference cited but not detailed.

—

Evidence basis

Animal mechanistic studies

Animal studies · In vitro assays

Route

Injectable (inferred from animal protocols)

—

Legal status

—

Controlled substance in many jurisdictions · Research only

Not approved for human use.

Animal research (ICV)

—

Low nanomolar to picomolar range

Intracerebroventricular administration in rodent models.

Detection limit (doping)

—

5 pg/mL in equine plasma/urineSteel 2014

High-throughput LC-MS/MS screen developed for racing industry.

Duration of action

—

10–120 minutes (dose-dependent, intrathecal)

Human toxicity

—

Kambô ritual (P. bicolor skin) — violent emesis, vasodilation, fluid shifts, ADH dysregulationTran 2025

04Side Effects & Safety

Parameter

Cortagen

Dermorphin

Antioxidant suppression

Suppression of antioxidant activity noted alongside LPO reductionKozina 2007

Mechanism unclear — possible homeostatic adaptation.

—

Immune/hemostasis effects

No effect on immunity or hemostasis parameters in avian hypophysectomy model (unlike epithalon)Kuznik 2008

Epithalon reversed deficits; cortagen did not.

—

Human safety data

No adverse events reported in peripheral nerve recovery context

Limited detail in available abstracts.

—

Opioid effects

—

Respiratory depression, sedation, euphoria, tolerance, dependence risk

CNS effects

—

Analgesia (high-affinity sites), catalepsy (low-affinity sites)Negri 1992

Kambô ritual toxicity

—

Violent emesis, vasodilation, profound fluid shifts, hyponatremia, ADH dysregulation, brain death (case report)Tran 2025

Peripheral effects

—

GI motility inhibition (ileum > vas deferens in vitro)Negri 1992

Receptor selectivity caveat

—

Two μ-receptor subtypes — differential behavioral effects (analgesia vs. catalepsy)Negri 1992

Proteolytic stability

—

Tyr³-Pro⁶ bond relatively unstable; endogenous enzymes may produce tetrapeptide fragmentsCucumel 1996

Absolute Contraindications

Cortagen

—

Dermorphin

·Human use — not approved by any regulatory authority
·Controlled substance status — possession illegal in many jurisdictions
·Known opioid hypersensitivity or respiratory compromise

Relative Contraindications

Cortagen

—

Dermorphin

·Any context outside approved animal research protocols
·CNS depressant co-administration

05Administration Protocol

Parameter

Cortagen

Dermorphin

1. Preparation

Reconstitute lyophilised peptide with bacteriostatic water per supplier protocol. Exact volumes depend on concentration supplied.

Dermorphin is a controlled substance in many jurisdictions and is not approved for human use. Possession, synthesis, or distribution may be illegal. Use is restricted to licensed research settings under institutional review.

2. Injection site

Subcutaneous injection typical for bioregulatory peptides — abdomen or thigh. Rotate sites.

In rodent models, intracerebroventricular (ICV) or intrathecal injection is used at nanomolar to picomolar concentrations. Subcutaneous administration also documented. All protocols require IACUC approval.

3. Timing

Animal protocols used repeated dosing over weeks. Human timing not established — evening administration common in Khavinson tradition.

High-throughput LC-MS/MS screens developed for anti-doping programs detect dermorphin and 17 related peptides in equine and human urine/plasma at limits as low as 5 pg/mL.Steel 2014

4. Storage

Lyophilised: refrigerate or freeze per supplier. Reconstituted: refrigerate 2–8 °C, use within guideline window.

Application of Phyllomedusa bicolor skin secretions to superficial burns. Not recommended — associated with severe toxicity including violent emesis, hyponatremia, and documented case of brain death.Tran 2025